Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CANAGLIFLOZIN Cause Product use issue? 317 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 317 reports of Product use issue have been filed in association with CANAGLIFLOZIN (INVOKANA). This represents 1.3% of all adverse event reports for CANAGLIFLOZIN.

317
Reports of Product use issue with CANAGLIFLOZIN
1.3%
of all CANAGLIFLOZIN reports
7
Deaths
150
Hospitalizations

How Dangerous Is Product use issue From CANAGLIFLOZIN?

Of the 317 reports, 7 (2.2%) resulted in death, 150 (47.3%) required hospitalization, and 16 (5.0%) were considered life-threatening.

Is Product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CANAGLIFLOZIN. However, 317 reports have been filed with the FAERS database.

What Other Side Effects Does CANAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,413) Toe amputation (2,193) Osteomyelitis (2,146) Acute kidney injury (1,853) Fungal infection (1,385) Gangrene (1,081) Weight decreased (1,014) Cellulitis (1,007) Urinary tract infection (920) Diabetic foot infection (832)

What Other Drugs Cause Product use issue?

INFLIXIMAB (12,752) DUPILUMAB (10,575) POLYETHYLENE GLYCOL 3350 (9,432) METHOTREXATE (8,185) DICLOFENAC (8,009) RITUXIMAB (6,948) ADALIMUMAB (6,379) ETANERCEPT (6,062) TOCILIZUMAB (5,944) ABATACEPT (5,915)

Which CANAGLIFLOZIN Alternatives Have Lower Product use issue Risk?

CANAGLIFLOZIN vs CANAGLIFLOZIN\METFORMIN CANAGLIFLOZIN vs CANAKINUMAB CANAGLIFLOZIN vs CANDESARTAN CANAGLIFLOZIN vs CANDESARTAN CILEXETIL CANAGLIFLOZIN vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE

Related Pages

CANAGLIFLOZIN Full Profile All Product use issue Reports All Drugs Causing Product use issue CANAGLIFLOZIN Demographics